| Heading: |
Obesity: Drugs and Exercise |
| Question ID: |
1805076 |
| UIN: |
54058 |
| House: |
Commons |
| Date tabled: |
2025-05-21 |
| Asking Member ID: |
5055 |
| Asking Member display name: |
Max Wilkinson
|
| Asking Member handle: |
mpmwilko
|
| Asking Member Twitter reference: |
@mpmwilko
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of the prescription of weight loss drugs on the NHS without associated prescriptions of exercise and physical activity on muscl |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-06 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4981 |
| Answering Member display name: |
Ashley Dalton
|
| Answering Member handle: |
AshleyDalton_MP
|
| Answering Member Twitter reference: |
@AshleyDalton_MP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Weight loss drugs, including semaglutide, tirzepatide and liraglutide, are recommended by the National Institute for Health and Care Excellence (NICE) as clinically and cost-effective treatment options on the National Health Service for obesity. The guida... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |